{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:05:44Z","timestamp":1781651144968,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015322","name":"National Cancer Center Japan","doi-asserted-by":"publisher","award":["19EA1011"],"award-info":[{"award-number":["19EA1011"]}],"id":[{"id":"10.13039\/100015322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Although opioids have been shown to be effective for cancer pain, opioid-induced adverse events (AEs) are common. To date, little is known about the differences in risks of AEs by opioid type. This study was performed to compare the prevalence of AEs across opioids commonly used for analgesic treatment in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was conducted as a preplanned secondary analysis of a multicenter prospective longitudinal study of inpatients with cancer pain who received specialized palliative care for cancer pain relief. We assessed daily AEs until termination of follow-up. We rated the severity of AEs based on the Common Terminology Criteria for Adverse Events version 5.0. We computed adjusted odds ratios for each AE (constipation, nausea and vomiting, delirium, and drowsiness) with the following variables: opioid, age, sex, renal dysfunction, and primary cancer site.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 465 patients were analyzed. Based on the descriptive analysis, the top four most commonly used opioids were included in the analysis: oxycodone, hydromorphone, fentanyl, and tramadol. With respect to the prevalence of AEs among all analyzed patients, delirium (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925, 6.3%) was the most frequent, followed by drowsiness (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921, 5.3%), nausea and vomiting (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919, 4.8%), and constipation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928, 4.6%). The multivariate logistic analysis showed that no single opioid was identified as a statistically significant independent predictor of any AE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There was no significant difference in the prevalence of AEs among oxycodone, fentanyl, hydromorphone, and tramadol, which are commonly used for analgesic treatment in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-023-08099-2","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:01:54Z","timestamp":1697428914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study"],"prefix":"10.1007","volume":"31","author":[{"given":"Yusuke","family":"Hiratsuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Tagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maika","family":"Natsume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Ishiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naosuke","family":"Yokomichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Wei","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Shigeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunori","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"8099_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jpainsymman.2009.12.023","volume":"40","author":"K Kroenke","year":"2010","unstructured":"Kroenke K, Theobald D, Wu J, Loza JK, Carpenter JS, Tu W (2010) The association of depression and pain with health-related quality of life, disability, and health care use in cancer patients. J Pain Symptom Manage 40:327\u2013341. https:\/\/doi.org\/10.1016\/j.jpainsymman.2009.12.023","journal-title":"J Pain Symptom Manage"},{"key":"8099_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cancers15030591","volume":"15","author":"RAH Snijders","year":"2023","unstructured":"Snijders RAH, Brom L, Theunissen M et al (2023) Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers (Basel) 15:591","journal-title":"Cancers (Basel)"},{"key":"8099_CR3","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","volume":"13","author":"A Caraceni","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58\u2013e68","journal-title":"Lancet Oncol"},{"key":"8099_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.6004\/jnccn.2018.0044","volume":"16","author":"RA Swarm","year":"2018","unstructured":"Swarm RA, Dans M (2018) NCCN frameworks for resource stratification of NCCN guidelines: adult cancer pain and palliative care. J Natl Compr Canc Netw 16:628\u2013631","journal-title":"J Natl Compr Canc Netw"},{"key":"8099_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jpainsymman.2019.02.009","volume":"57","author":"O Corli","year":"2019","unstructured":"Corli O, Santucci C, Corsi N et al (2019) The burden of opioid adverse events and the influence on cancer patients\u2019 symptomatology. J Pain Symptom Manage 57:899-908.e6","journal-title":"J Pain Symptom Manage"},{"key":"8099_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jpain.2015.05.006","volume":"16","author":"AW Oosten","year":"2015","unstructured":"Oosten AW, Oldenmenger WH, Mathijssen RH et al (2015) A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain 16:935\u2013946","journal-title":"J Pain"},{"key":"8099_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/jpm.2018.0260","volume":"22","author":"TA Sande","year":"2019","unstructured":"Sande TA, Laird BJA, Fallon MT (2019) The management of opioid-induced nausea and vomiting in patients with cancer: a systematic review. J Palliat Med 22:90\u201397","journal-title":"J Palliat Med"},{"key":"8099_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3322\/canjclin.50.2.70","volume":"50","author":"N Cherny","year":"2000","unstructured":"Cherny N (2000) The management of cancer pain. CA Cancer J Clin 50:70\u2013120","journal-title":"CA Cancer J Clin"},{"key":"8099_CR9","first-page":"1837","volume":"18","author":"S M\u00fcller-Lissner","year":"2017","unstructured":"M\u00fcller-Lissner S, Bassotti G, Coffin B et al (2017) Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med 18:1837\u20131863","journal-title":"Pain Med"},{"key":"8099_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","volume":"8","author":"J Pergolizzi","year":"2008","unstructured":"Pergolizzi J, B\u00f6ger RH, Budd K et al (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8:287\u2013313","journal-title":"Pain Pract"},{"key":"8099_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jpainsymman.2019.02.006","volume":"57","author":"A Kotlinska-Lemieszek","year":"2019","unstructured":"Kotlinska-Lemieszek A, Klepstad P, Haugen DF (2019) Clinically significant drug-drug interactions involving medications used for symptom control in patients with advanced malignant disease: a systematic review. J Pain Symptom Manage 57:989-998.e1","journal-title":"J Pain Symptom Manage"},{"key":"8099_CR12","first-page":"CD012592","volume":"7","author":"PJ Wiffen","year":"2017","unstructured":"Wiffen PJ, Wee B, Derry S et al (2017) Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev 7:CD012592","journal-title":"Cochrane Database Syst Rev"},{"key":"8099_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41687-017-0012-7","volume":"1","author":"T Miyaji","year":"2017","unstructured":"Miyaji T, Iioka Y, Kuroda Y et al (2017) Japanese translation and linguistic validation of the US National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Patient Rep Outcomes 1:8","journal-title":"J Patient Rep Outcomes"},{"key":"8099_CR14","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jpainsymman.2009.06.001","volume":"38","author":"H Knotkova","year":"2009","unstructured":"Knotkova H, Fine PG, Portenoy RK (2009) Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 38:426\u2013439","journal-title":"J Pain Symptom Manage"},{"key":"8099_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","volume":"17","author":"RA Swarm","year":"2019","unstructured":"Swarm RA, Paice JA, Anghelescu DL et al (2019) Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17:977\u20131007","journal-title":"J Natl Compr Canc Netw"},{"key":"8099_CR16","first-page":"CD011056","volume":"2014","author":"PJ Wiffen","year":"2014","unstructured":"Wiffen PJ, Derry S, Moore RA (2014) Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev 2014:CD011056","journal-title":"Cochrane Database Syst Rev"},{"key":"8099_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/jpm.2014.0122","volume":"18","author":"R Yamamoto","year":"2015","unstructured":"Yamamoto R, Kizawa Y, Nakazawa Y et al (2015) Outcome evaluation of the palliative care emphasis program on symptom management and assessment for continuous medical education: nationwide physician education project for primary palliative care in Japan. J Palliat Med 18:45\u201349","journal-title":"J Palliat Med"},{"key":"8099_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a058765","volume":"5","author":"CH Wilder-Smith","year":"1994","unstructured":"Wilder-Smith CH, Schimke J, Osterwalder B et al (1994) Oral tramadol, a \u03bc-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 5:141\u2013146","journal-title":"Ann Oncol"},{"key":"8099_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1177\/0269216311401948","volume":"25","author":"SJ King","year":"2011","unstructured":"King SJ, Reid C, Forbes K et al (2011) A systematic review of oxycodone in the management of cancer pain. Palliat Med 25:454\u2013470","journal-title":"Palliat Med"},{"key":"8099_CR20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/0269216310387962","volume":"25","author":"A Pigni","year":"2011","unstructured":"Pigni A, Brunelli C, Caraceni A (2011) The role of hydromorphone in cancer pain treatment: a systematic review. Palliat Med 25:471\u2013477","journal-title":"Palliat Med"},{"key":"8099_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11894-017-0560-2","volume":"19","author":"DM Brenner","year":"2017","unstructured":"Brenner DM, Stern E, Cash BD (2017) Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr Gastroenterol Rep 19:12","journal-title":"Curr Gastroenterol Rep"},{"issue":"Suppl 4","key":"8099_CR22","doi-asserted-by":"publisher","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","volume":"29","author":"PJ Larkin","year":"2018","unstructured":"Larkin PJ, Cherny NI, La Carpia D et al (2018) Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol 29(Suppl 4):iv111\u2013iv125","journal-title":"Ann Oncol"},{"key":"8099_CR23","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","volume":"35","author":"N Katakami","year":"2017","unstructured":"Katakami N, Harada T, Murata T et al (2017) Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol 35:3859\u20133866","journal-title":"J Clin Oncol"},{"key":"8099_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00520-019-04884-0","volume":"28","author":"J Sato","year":"2020","unstructured":"Sato J, Tanaka R, Ishikawa H et al (2020) A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting. Support Care Cancer 28:1083\u20131088","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08099-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T05:07:13Z","timestamp":1702530433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08099-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8099"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08099-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3153774\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"9 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have reported the COI via ICMJE disclosure form. The corresponding author has submitted the forms as supplementary files.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study obtained was approved by the independent ethics committee of Tohoku University School of Medicine (approval no. 2020\u20131-1085).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"In accordance with the ethical guidelines for human research of the Ministry of Health, Labor, and Welfare in Japan, patients\u2019 informed consent was waived in Japan because of the completely observational nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"632"}}